Infectious Disease Clinical Trials Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The infectious disease clinical trials sector is poised for significant expansion in the coming years, driven by advancements in technology and heightened global health priorities. This market is steadily evolving as new methods and innovations emerge, reshaping how trials are designed and conducted worldwide.

Forecasted Market Growth in Infectious Disease Clinical Trials
The infectious disease clinical trials market is projected to expand robustly, reaching a valuation of $21.25 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 7.1%. Key factors fueling this increase include amplified investments in pandemic preparedness, the broader adoption of AI-based patient recruitment techniques, the ongoing decentralization of global clinical trials, a stronger focus on expedited regulatory approvals, and the enhanced use of digital biomarkers. Throughout the forecast period, trends such as data-centric trial designs, decentralized clinical models, integration of real-world evidence, adaptive study methodologies, and rapid response mechanisms to emerging pathogens are expected to shape the market's trajectory.

The infectious disease clinical trials market size has grown strongly in recent years. It will grow from $15.1 billion in 2025 to $16.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to expansion of global infectious disease burden, increased funding for vaccine development, growth in multinational clinical trial networks, adoption of digital trial management systems, rising public health research initiatives.

Download a free sample of the infectious disease clinical trials market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=29097&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Primary Drivers Accelerating the Infectious Disease Clinical Trials Market
One of the main forces behind the market's growth is the surge in investments aimed at better pandemic preparedness, which has become a global priority following recent health crises. This increased funding is supporting more extensive and sophisticated clinical trial activities.

Additionally, the integration of AI technologies has revolutionized patient recruitment, making trials more efficient and inclusive. AI-assisted recruitment helps identify suitable candidates faster, reducing delays and improving trial outcomes. Such technological advancements are pivotal in driving the market forward.

View the full infectious disease clinical trials market report:
https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Industry Players Leading the Infectious Disease Clinical Trials Field
The infectious disease clinical trials sector includes numerous prominent companies shaping its landscape. These industry leaders include GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, and Genentech Infectious Diseases Unit.

Strategic Acquisition Expanding Clinical Trial Reach
In February 2025, Flourish Research LLC, a US-based organization specializing in multi-site clinical trials, acquired Diablo Clinical Research LLC for an undisclosed sum. This acquisition is designed to broaden Flourish Research LLC's geographical reach and expand its therapeutic area expertise, thereby enhancing its capacity to conduct infectious disease clinical trials. Diablo Clinical Research LLC also operates within the US and focuses on infectious disease trials.

Emerging Trends Shaping the Future of Infectious Disease Clinical Trials
Leading companies in this market are prioritizing advanced research efforts, including late-stage phase 3 trials for new antibiotic candidates. These trials are essential to detect rare side effects and establish the most effective dosing regimens.

For example, in May 2025, Roche, headquartered in Switzerland, initiated a Phase 3 clinical trial for zosurabalpin, a new tethered macrocyclic peptide antibiotic aimed at combating carbapenem-resistant Acinetobacter baumannii (CRAB), a major cause of serious hospital infections worldwide. Zosurabalpin operates through a novel mechanism that inhibits the transport of lipopolysaccharides crucial for bacterial outer membrane formation, with no resistance reported to date. The global trial will include around 400 patients to assess its safety and efficacy in comparison with existing treatments. Preliminary studies have demonstrated strong activity against multidrug-resistant bacteria, excellent tolerability, and favorable pharmacokinetic profiles, positioning it as a promising candidate in the fight against antibiotic resistance.

Detailed Segmentation of the Infectious Disease Clinical Trials Market
This market is analyzed across multiple dimensions, including:

1) Phase of Clinical Trial: Phase I, Phase II, Phase III, Phase IV
2) Indication: Human Immunodeficiency Virus (HIV), Hepatitis, Influenza, Tuberculosis, Malaria, COVID-19, and other infectious diseases
3) Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies
4) Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, and Combination Therapies
5) End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations, Academic Institutions, and other users

Further sub-segmentations include:
- Phase I: Healthy volunteer trials, dose-escalation studies, safety and tolerability assessments, and pharmacokinetic/pharmacodynamic studies
- Phase II: Early efficacy testing, proof-of-concept studies, population-specific research, and short-term safety evaluations
- Phase III: Large-scale efficacy trials, comparative effectiveness research, multi-center clinical trials, and extended safety monitoring
- Phase IV: Post-marketing surveillance, long-term safety studies, real-world evidence generation, and special population assessments

This comprehensive breakdown offers a clear understanding of the market's structure and highlights areas of focus within infectious disease clinical research.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.